Mouse IL15 Recombinant

Mouse IL15 Recombinant

$60.00$3,500.00

SKU: RKP48346 Category: Tags: , , ,

accession P48346


Source Optimized DNA sequence encoding mouse Interleukin-15 mature chain was expressed in Escherichia Coli.
Molecular weight Native mouse Interleukin-15 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 13 kDa. Recombinant mouse Interleukin-15 is a monomer protein consisting of 115 amino acid residue subunits, and migrates as an approximately 13kDa protein under reducing conditions in SDS-PAGE.
Purity >95%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the dose-dependent proliferation of murine CTLL-2 cells is < 2.0 ng/ml.

Protein Sequence MKILKPYMRN TSISCYLCFL LNSHFLTEAG IHVFILGCVS VGLPKTEANW IDVRYDLEKI ESLIQSIHID TTLYTDSDFH PSCKVTAMNC FLLELQVILH EYSNMTLNET VRNVLYLANS TLSSNKNVAE SGCKECEELE EKTFTEFLQS FIRIVQMFIN TS
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation Recombinant mouse IL-15 was lyophilized from a 0.2 μm filtered PBS solution.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least 2 years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Molecular function Cytokine

Methods

Comparisons are made for ΔMFI of CD86, HLA-DR and CCR7 expression between DCs with either HLA-C1 or HLA-C2 homozygous allele.

1 ng/ml IL-15
  • Data shown are ΔMFI of CD86, HLA-DR and CCR7 expressed by DC in NK-DC co-culture in the presence of 1 ng/ml IL-15 at cell ratios of either 1∶1 or 1∶5.

Functional assays

  • For cytokine signalling, LN T cells (5 × 106 cells/ml) were cultured 16 h with recombinant mouse IL-7 (10 ng/ml), IL-4 (40 ng/ml), IL-6 (45 ng/ml& ) or IL-15 (100 ng/ml& ) as previously described (

TGF-β is a negative regulator of NK cell generation CD11cdnR and wild-type mice were injected (i.p.)

30 ng/ml murine IL-15
  • On day 5, cells were harvested, plated on OP9 stromal cells, and cultured in the presence of IL-15.

PLZF regulates the expression of c-Maf.

100 ng/mL IL-15
  • iNKT cell were sorted from thymi and spleens of WT or PLZFlu/lu mice, cultured for 2 days in the presence of IL-7 and IL-15, infected with IRES-GFP or c-Maf-IRES-GFP retroviruses and stimulated with PMA/Ionomycin 2 days after infection.

In vitro BrdU incorporation assays

  • CD8+ T cells were isolated and co-cultured with OVA(257–264) -pulsed irradiated splenocytes in 24-well plates in 10% FCS RPMI.
  • On day 3 cells 30U/ml of rIL-2 were added.
  • Cells were treated with 1-1000 U/ml rIFNβ1 for the duration of the culture.
  • Cells were harvested on days 3 or 5.
  • BrdU (10μM) was added during the last 8h, cells were stained with FITC-conjugated anti-BrdU antibody (clone BU20a, eBioscience) and BrdU labeling was determined by flow cytometry.
  • In some experiments, rIFNβ1 was added after day 3 of culture and cells were harvested on day 6.
  • In these day 6 cultures, 2ng/ml of murine rIL-7 and rIL-15 and 5 U/ml of rIL-2 were also added on day 3.

Impaired IL-15 signaling in TRAF3-deficient CD8+ Tcm cells.

IL-15
  • Splenocytes were stimulated with 20/ml IL-15 for 20 min.

IL-15/IL-15Rα complex administration

  • Soluble IL-15/IL-15Rα complexes were prepared as described previously (Ccr7 mice.
  • Mice were sacrificed 4 d postinjection, and thymic samples were analyzed for iNKT cell populations by flow cytometry.

Ptpn22 restrains weak agonist-induced inflammatory cytokine production by effector CTLs.

IL-15
  • (e-j) CTLs were generated in vitro by N4 peptide stimulation followed by expansion and differentiation in IL-2 or IL-15.